NCT03213002View on ClinicalTrials.gov

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

June 13, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Glioblastoma Multiforme (GBM)GlioblastomaGlioma of BrainGlioblastoma, AdultBrain TumorBrain Tumor, PrimaryBrain Tumor AdultCancerBrain Cancer
Interventions
DRUG

Capecitabine

Capecitabine at 1500 mg/m2

DRUG

Temozolomide

Temozolomide at 150 mg/m2 - 200 mg/m2

Trial Locations (1)

10075

RECRUITING

Lenox Hill Brain Tumor Center, New York

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER